AMENIA TRADES

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ikunoshin KATO et al

Appln. No.: 09/937,375

Filed: September 24, 2001

For: GENE THERAPEUTICS

ATTY.'S DOCKET: KATO =18

Art Unit: 1642

Washington, D.C.

August 4, 2003

Confirmation No.: 8012

INFORMATION DISCLOSURE STATEMENT [IDS]

RECEIVED

Honorable Commissioner of Patents and Trademarks P.O. Box 1450 Alexandria, VA 22313-1450

AUG 0 5 2003

TECH CENTER 1600/2900

Sir:

7

This Information Disclosure Statement is submitted in accordance with 37 CFR §\$1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

- [X] 1. This IDS should be considered, in accordance with 37 CFR \$1.97, as it is filed before the mailing date of a first office action on the merits.
- [X] 2. In accordance with 37 CFR \$1.98, this IDS includes a list (e.g., form PTO/SB/08A) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached.

In re Appln. No. 09/937,375

[X] 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20). However, a concise explanation of relevance is being provided in the form of the attached <u>Supplementary Partial European</u> Search Report.

4. In accordance with 37 CFR §\$1.97(g) and (h), the filing of this IDS should not be construed representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in different.

Respectfully submitted,

BROWDY AND NEIMARK Attorneys for Applicant(s)

By:

Anne M. Kornbau Reg. No. 25,884

624 Ninth Street, N.W., Suite 300

Washington, D.C. 20001-5303

Telephone: (202)628-5197 Facsimile: (202)737-3528

:jaa

G:\BN\A\Aoyb\Kato18\PTO\ids 4au03.doc

Complete if Known

09/937,375

September 24, 2001

Ikunoshin KATO et al

O JO76 JOHN

ubstitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number

First Named Inventor

Filing Date

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²			
	AN	HARRINGTON et al, "Cells as Vehicles for Cancer Gene Therapy: The Missing Link Between Targeted Vectors and Systemic Delivery?", HUMAN GENE THERAPY, Vol. 13, 2002, pp. 1263-1280.				
1.07	AO	NAMBA et al, "Bystander Effect-Mediated Therapy of Experimental Brain Tumor by Genetically Engineered Tumor Cells" HUMAN GENE THERAPY, Vol. 9, 1998, pp. 5-11.				
-		RECEIVE	D			
		AUG 0 5 2003				
		TECH CENTER 1600/2	900			
Exami		Date Considered	7			

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



SUPPLEMENTARY PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent ConventionEP 00 90 8055 shall be considered, for the purposes of subsequent proceedings, as the European search report

		DOCUMENTS CONSID			
	Category	Citation of document with of relevant pas	indication, where appropriate, sages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.CI.7)
MO.	Υ	therapy of experime genetically engines HUMAN GENE THERAPY 1998, vol. 9, no. 1,	UNITED STATES 1 JAN 98-01-01), pages 5-11,	1-32	A61K48/00 A61K31/70 //(A61K31/70, 35:12,35:28, 35:30,38:02, 38:16,38:19, 38:22,38:43, 39:395)
AY	Y	RETROVIRUS AND TARGET FIBRONECTIN FRAGMENTRANSDUCTION OF MAN	GET CELLS ON SPECIFIC ITS INCREASES GENETIC IMALIAN CELLS" ATURE PUBLISHING, CO, 1996-08), 199228787	1-32	TECHNICAL FIELDS SEARCHED (Int.Cl.7) A61K
	The su	pplementary search report has t	C12N		
-		d available at the start of the sea MPLETE SEARCH			
	not comply be carried Claims sea	th Division considers that the present y with the EPC to such an extent that out, or can only be carried out partia arched completely:		c	
	Claims not	t searched :			
		r the limitation of the search: sheet C			
2					
ſ		Place of search MUNICH	Date of completion of the search 28 May 2003	Hod	er, A
12 (P04(C,	ATEGORY OF CITED DOCUMENTS	· · · · · · · · · · · · · · · · · · ·	<u>-</u>	
EPO FORM 1503 03.82 (P04C20)	X : parti Y : parti docu A : tech O : non-	icularly relevant if taken alone icularly relevant if combined with anounce of the same category nological background—written disclosure mediate document	shed on, or ,, corresponding		

European Pat nt Offic

SUPPLEMENTARY PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 00 90 8055

		DOCUMENTS CONSIDERED TO BE RELEVANT	CLASSIFICATION OF THE APPLICATION (Int.CI.7)	
	Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
NA	Ţ	HARRINGTON KEVIN ET AL: "Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery?"		
		HUMAN GENE THERAPY. UNITED STATES 20 JUL 2002, vol. 13, no. 11, 20 July 2002 (2002-07-20), pages 1263-1280, XP002242755 ISSN: 1043-0342		
				,
	÷			TECHNICAL FIELDS SEARCHED (Int.C1.7)
C26)				
EPO FORM 1503 09.98 (P04C26)				
PO FORM				